(S)-tert-butyl (3-cyclopentyl-1-(cyclopropylamino)-1-oxopropan-2-yl)carbamate, 97%, 250mg

(4R)-4-[(1S)-1-fluoroethyl]-3-(2-{[(1S)-1-[4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl]ethyl]amino}pyrimidin-4-yl)-1,3-oxazolidin-2-one, 5mg

Ethyl 3-phenylglycidate, 90.0%, 25g

tert-Butyl 2-(8-oxo-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetate, 98%, 25g

(R)-2-(Methylamino)-2-phenylethanol, 95+%, 100mg

(S)-2-Amino-3-(3-chloro-4-fluorophenyl)propanoic acid, 95%, 500mg

Methyl(3r,4s)-4-methylpiperidine-3-carboxylate;hydrochloride, 98%, 250mg

Colonne HPLC NUCLEODUR® NH2 5 µm, 250 mm, 4 mm, 1 pièce(s)

Tert-butyl 4-(piperidin-4-ylmethyl)piperidine-1-carboxylate, 98%, 100mg

Flacon à col étroit en aluminium avec homologation UN, 125 ml, 1 Pièce

2-Iodobenzoic Acid>98.0%(GC)(T)25g

Tert-butyl 2-cyano-2-[5-(trifluoromethyl)pyridin-2-yl]acetate, 97%, 1g

tert-Butyl N,N-dimethylcarbamate, 98%, 500mg